Dasatinib
Stage III Adult Diffuse Mixed Cell Lymphoma
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Stage III Adult Diffuse Mixed Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Case Comprehensive Cancer Center | Phase 2 | BBB |
Cyclophosphamide University of Chicago | Phase 2 | BBB |
Monomethyl Fumarate University of Nebraska | Phase 2 | BB |
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 2 | BB |
TACROLIMUS National Cancer Institute (NCI) | Phase 2 | BB |
View all 49 →
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →